Telesis Bio Analyst Ratings
Telesis Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 08/04/2021 | 2633.81% | Roth Capital | $45 → $38 | Maintains | Neutral |
| 08/03/2021 | 2633.81% | SVB Leerink | $19 → $38 | Maintains | Market Perform |
| 08/03/2021 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 07/26/2021 | 3137.41% | Roth Capital | $28 → $45 | Maintains | Buy |
| 05/10/2021 | 1266.91% | SVB Leerink | $18 → $19 | Maintains | Market Perform |
| 03/23/2021 | 1194.96% | SVB Leerink | $21 → $18 | Downgrades | Outperform → Market Perform |
| 03/18/2021 | 1914.39% | Roth Capital | $37 → $28 | Maintains | Buy |
| 03/18/2021 | 1914.39% | HC Wainwright & Co. | $32 → $28 | Maintains | Buy |
| 03/18/2021 | 1410.79% | SVB Leerink | $33 → $21 | Maintains | Outperform |
| 03/18/2021 | 1410.79% | Evercore ISI Group | → $21 | Downgrades | Outperform → In-Line |
| 03/18/2021 | 1338.85% | Truist Securities | → $20 | Downgrades | Buy → Hold |
| 03/01/2021 | 2274.1% | SVB Leerink | $34 → $33 | Maintains | Outperform |
| 11/09/2020 | 2346.04% | SVB Leerink | $30 → $34 | Reiterates | → Outperform |
| 10/05/2020 | 1266.91% | Goldman Sachs | → $19 | Initiates Coverage On | → Buy |
| 08/19/2020 | 2346.04% | Citigroup | $35 → $34 | Maintains | Buy |
| 07/07/2020 | 2202.16% | HC Wainwright & Co. | $18 → $32 | Maintains | Buy |
| 07/06/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 06/26/2020 | 2058.27% | SVB Leerink | $21 → $30 | Maintains | Outperform |
| 06/26/2020 | 2777.7% | SunTrust Robinson Humphrey | → $40 | Initiates Coverage On | → Buy |
| 07/22/2019 | 1338.85% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 06/18/2019 | 1698.56% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 12/24/2018 | 1410.79% | HC Wainwright & Co. | → $21 | Initiates Coverage On | → Buy |
| 11/14/2018 | 1698.56% | Leerink Swann | $24 → $25 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/11/2023 | — | Keybanc | 降級 | 增持 → 行業權重 | |
| 08/04/2021 | 2633.81% | 羅斯資本 | 45 美元 → 38 美元 | 維護 | 中立 |
| 08/03/2021 | 2633.81% | SVB Leerink | 19 美元 → 38 美元 | 維護 | 市場表現 |
| 08/03/2021 | — | 威廉布萊爾 | 降級 | 跑贏大盤 → 市場表現 | |
| 2021 年 7 月 26 日 | 3137.41% | 羅斯資本 | 28 美元 → 45 美元 | 維護 | 購買 |
| 2021 年 10 月 5 日 | 1266.91% | SVB Leerink | 18 美元 → 19 美元 | 維護 | 市場表現 |
| 2021 年 3 月 23 日 | 1194.96% | SVB Leerink | 21 美元 → 18 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 03/18/2021 | 1914.39% | 羅斯資本 | 37 美元 → 28 美元 | 維護 | 購買 |
| 03/18/2021 | 1914.39% | HC Wainwright & Co. | 32 美元 → 28 美元 | 維護 | 購買 |
| 03/18/2021 | 1410.79% | SVB Leerink | 33 美元 → 21 美元 | 維護 | 跑贏大盤 |
| 03/18/2021 | 1410.79% | Evercore ISI 集團 | → 21 美元 | 降級 | 跑贏大盤 → 在線 |
| 03/18/2021 | 1338.85% | 信託證券 | → 20 美元 | 降級 | 買入 → 持有 |
| 2021 年 1 月 3 日 | 2274.1% | SVB Leerink | 34 美元 → 33 美元 | 維護 | 跑贏大盤 |
| 11/09/2020 | 2346.04% | SVB Leerink | 30 美元 → 34 美元 | 重申 | → 跑贏大盤 |
| 2020 年 5 月 10 日 | 1266.91% | 高盛 | → 19 美元 | 啓動覆蓋開啓 | → 購買 |
| 2020 年 8 月 19 日 | 2346.04% | 花旗集團 | 35 美元 → 34 美元 | 維護 | 購買 |
| 2020 年 7 月 7 日 | 2202.16% | HC Wainwright & Co. | 18 美元 → 32 美元 | 維護 | 購買 |
| 2020 年 6 月 7 日 | — | 威廉布萊爾 | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 2020 年 6 月 26 日 | 2058.27% | SVB Leerink | 21 美元 → 30 美元 | 維護 | 跑贏大盤 |
| 2020 年 6 月 26 日 | 2777.7% | SunTrust 羅賓遜漢弗萊 | → 40 美元 | 啓動覆蓋開啓 | → 購買 |
| 07/22/2019 | 1338.85% | 傑富瑞 | → 20 美元 | 啓動覆蓋開啓 | → 購買 |
| 06/18/2019 | 1698.56% | 羅斯資本 | → 25 美元 | 啓動覆蓋開啓 | → 購買 |
| 12/24/2018 | 1410.79% | HC Wainwright & Co. | → 21 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/14/2018 | 1698.56% | Leerink Swann | 24 美元 → 25 美元 | 維護 | 跑贏大盤 |
What is the target price for Telesis Bio (TBIO)?
Telesis Bio（TBIO）的目標價格是多少？
The latest price target for Telesis Bio (NASDAQ: TBIO) was reported by Keybanc on August 11, 2023. The analyst firm set a price target for $0.00 expecting TBIO to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
Keybanc於2023年8月11日公佈了Telesis Bio（納斯達克股票代碼：TBIO）的最新目標股價。這家分析公司將目標股價定爲0.00美元，預計TBIO將在12個月內跌至-100.00％（可能下跌-100.00％）。去年有1家分析公司公佈了評級。
What is the most recent analyst rating for Telesis Bio (TBIO)?
分析師對Telesis Bio（TBIO）的最新評級是多少？
The latest analyst rating for Telesis Bio (NASDAQ: TBIO) was provided by Keybanc, and Telesis Bio downgraded their sector weight rating.
Telesis Bio（納斯達克股票代碼：TBIO）的最新分析師評級由Keybanc提供，Telesis Bio下調了其行業權重評級。
When is the next analyst rating going to be posted or updated for Telesis Bio (TBIO)?
Telesis Bio（TBIO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Telesis Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Telesis Bio was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Telesis Bio的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Telesis Bio的最後一次評級是在2023年8月11日提交的，因此你應該預計下一個評級將在2024年8月11日左右公佈。
Is the Analyst Rating Telesis Bio (TBIO) correct?
分析師對 Telesis Bio (TBIO) 的評級正確嗎？
While ratings are subjective and will change, the latest Telesis Bio (TBIO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Telesis Bio (TBIO) is trading at is $1.39, which is out of the analyst's predicted range.
雖然收視率是主觀的，會發生變化，但最新的Telesis Bio（TBIO）評級被下調，目標股價爲0.00美元至0.00美元。Telesis Bio（TBIO）目前的交易價格爲1.39美元，超出了分析師的預測區間。